ArticleScience advances2026
An injectable, leadless bioelectronic interface for battery-free wireless peripheral neuromodulation.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Injectable bioelectronics offer a minimally invasive approach to peripheral nerve stimulation but remain limited by onboard energy storage and fragile leads. Here, we present SEED, a leadless, battery-free bioelectronic interface engineered for percutaneous delivery through a standard 14-gauge needle. SEED (Stimulating Electrode for Electroceutical Delivery) operates in the magnetoquasistatic regime using low-frequency (65 kilohertz) resonant inductive coupling, externalizing waveform generation and control, enabling programmable neuromodulation without onboard active electronics. A spiral-helix electrode geometry promotes longitudinal nerve engagement while limiting off-target field spread. Benchtop and ex vivo characterization demonstrates precise, programmable control of stimulation frequency, pulse width, and amplitude under physiologically relevant conditions. In vivo validation in a rat sciatic nerve model confirms frequency-locked motor responses and graded neural recruitment following percutaneous deployment. SEED exhibits strong radiopacity and acoustic contrast, supporting compatibility with ultrasound and computed tomography for image-guided neuromodulation. This platform provides a scalable pathway toward minimally invasive bioelectronic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.